The epidemiology of inflammatory bowel disease: East meets west

WY Mak, M Zhao, SC Ng… - Journal of gastroenterology …, 2020 - Wiley Online Library
The incidence of inflammatory bowel diseases (IBD) in East has risen over the past decade
to become a global disease. The increasing number of studies on the incidence and course …

The burden of inflammatory bowel disease in Europe in 2020

M Zhao, L Gönczi, PL Lakatos… - Journal of Crohn's and …, 2021 - academic.oup.com
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are
still increasing worldwide, and approximately 0.2% of the European population suffer from …

AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease

JD Feuerstein, EY Ho, E Shmidt, H Singh… - …, 2021 - gastrojournal.org
Methods This document presents the official recommendations of the AGA on the medical
management of moderate to severe luminal and fistulizing CD in adults. This guideline …

The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot …

H Yanai, A Levine, A Hirsch, RS Boneh… - The Lancet …, 2022 - thelancet.com
Summary Background The Crohn's disease exclusion diet (CDED) with partial enteral
nutrition is effective for induction of remission in children with mild-to-moderate Crohn's …

The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission

J Burisch, M Zhao, S Odes, P De Cruz… - The Lancet …, 2023 - thelancet.com
The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Deep remission at 1 year prevents progression of early Crohn's disease

RC Ungaro, C Yzet, P Bossuyt, FJ Baert, T Vanasek… - Gastroenterology, 2020 - Elsevier
Background & Aims We investigated the effects of inducing deep remission in patients with
early Crohn's disease (CD). Methods We collected follow-up data from 122 patients (mean …

[HTML][HTML] Disease monitoring in inflammatory bowel disease: evolving principles and possibilities

N Plevris, CW Lees - Gastroenterology, 2022 - Elsevier
Inflammatory bowel disease is a progressive and debilitating condition. Early and effective
treatment utilizing a treat to target approach is key in improving patient outcomes. Therefore …

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR! C trial

TW Stevens, ML Haasnoot, GR D'Haens… - The lancet …, 2020 - thelancet.com
Summary Background The LIR! C trial showed that laparoscopic ileocaecal resection is a
cost-effective treatment that has similar quality-of-life outcomes to treatment with infliximab …

Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD

C Le Berre, L Peyrin-Biroulet, WJ Sandborn… - Gastroenterology, 2021 - Elsevier
Background and Aims Inflammatory bowel diseases (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic and disabling disorders. Prospective disease …

Breaking through the therapeutic ceiling: what will it take?

T Raine, S Danese - Gastroenterology, 2022 - Elsevier
Outcomes for patients starting a new treatment for inflammatory bowel disease are
characterized by uncertainty of treatment response. Although it is natural to hope that new …